PA
TEVA icon

PFW Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

PFW Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-26,295
Closed -$821K – 130
2025
Q4 		$821K Hold
26,295
– – 0.25% 69
2025
Q3 		$531K Hold
26,295
– – 0.16% 84
2025
Q2 		$441K Buy
26,295
+313
+1% +$5.05K 0.14% 90
2025
Q1 		$399K Sell
25,982
-8
-0% -$143 0.13% 91
2024
Q4 		$573K Buy
+25,990
New +$473K 0.18% 82
2024
Q2 		$422K Buy
25,982
+543
+2% +$8.36K 0.13% 90
2024
Q1 		$359K Buy
25,439
+121
+0.5% +$1.52K 0.11% 96
2023
Q4 		$264K Buy
25,318
+318
+1% +$2.97K 0.08% 105
2023
Q3 		$255K Hold
25,000
– – 0.09% 103
2023
Q2 		$245K Buy
+25,000
New +$203K 0.08% 109
2019
Q3 		$468K Buy
+25,982
New +$199K 0.14% 90

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PFW Advisors's TEVA Position: Q1 2026 in Review

PFW Advisors sold out of Teva Pharmaceuticals (TEVA) in Q1 2026, closing a stake of 26,295 shares — an estimated $821K sold.

PFW Advisors first reported a position in TEVA in Q3 2019 and held it in 11 quarters. The position peaked at $821K in Q4 2025. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • PFW Advisors reported no remaining Teva Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • PFW Advisors sold 26,295 Teva Pharmaceuticals shares in Q1 2026, an estimated $821K.
  • PFW Advisors first reported a position in Teva Pharmaceuticals in Q3 2019 and held it in 11 quarters.
  • PFW Advisors's Teva Pharmaceuticals position peaked at $821K in Q4 2025.
  • 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on PFW Advisors's 13F filing for Q1 2026, filed 10 Apr 2026.